This advanced-level course is designed to develop an understanding of complex concepts related to genomics, particularly CRISPR/Cas technology and its applications in drug discovery, therapeutics and much more.
This advanced course is designed for a wide range of professionals with a background in bioscience and preferably with a basic knowledge of CRISPR/Cas technology. Undergraduate or graduates and postgraduate scholars, researchers, academicians such as lecturers and professors, investors or venture capitalists, policymakers, and other industry professionals who are capable of self-learning are likely to benefit from this course. The course will also be beneficial to those looking for career opportunities in the field of CRISPR/Cas technology and genomics.
Dr. Christos Evangelou
PhD in Cancer Biology, Division of Molecular and Clinical Cancer Sciences, University of Manchester, UK. Areas of expertise include cancer immunology, melanoma research, cancer immunotherapy, and mechanisms of immunotherapy resistance. During my PhD research, I studied the role of chronic inflammation and the cytokine IFN-gamma in adaptation and immunotherapy resistance in melanoma. By integrating high-throughput transcriptomic analyses and employing various cancer cell lines and animal models, I have developed methods to predict response to immunotherapy in melanoma patients. During my research, I have used the CRISPR/Cas9 system to knockout genes in human and mouse cell lines to assess the role of certain genes in immunotherapy resistance in melanoma.
Dr. Veronica Hughes
Veronica Hughes received her PhD in medical science from the University of Florida. Her primary interest was cancer metastasis, dysregulation of the tumour microenvironment, and analysis of clinical trial design. Additionally, she engaged in the development of novel small animal models.
Dr. Matthias Schröder
PhD in Immunology at the Division of Immunopharmacology of the University Clinic of Frankfurt am Main. Involved in basic and applied research for immunological interventions to treat cancer for 13 years. Matthias used a high-throughput CRISPR/Cas9 approach to generate a library of knockout cells that could be differentiated in immunosuppressive cells to investigate potential loss of function situations. Currently involved in the development of fusion proteins to activate receptors of the TNF-superfamily (CD40, CD27 etc.) at a small German Biotech company as Head of Assay Development.
Train your employees and/or students in the most in demand topics, with CBEHx for Business and School.
The CBEHx for School domain empowers universities, schools, and other educational organizations with career-targeted transformative knowledge and skill development programs.
The price of each course is indicated on the respective course page. The course price usually ranges from £50 to £120.
Usually, there are no general prerequisites when enrolling for any individual courses on cbehx.co.uk. However, some courses are certainly more advanced than others that are of introductory and intermediate level. For advanced-level courses, prior knowledge on the topic will be helpful for understanding complex concepts but not mandatory.
The relevant information about the suggested knowledge and background that might be helpful to follow each course is provided on the respective course registration page.
Yes, the courses are flexible and self-paced to suit your schedule. The term “self-paced” implies that the courses do not follow a pre-assigned schedule for learning within the course duration. You will be able to access all the course materials for each course that you have enrolled in as soon as the course begins.
Sure, it is possible! You are free to enrol in multiple CBEHx courses at a time. However, we strongly suggest that you check the requirements and details for each course on their respective course pages so that you can easily strike a balance between your daily work/study schedules and the demands of each course.
No, the courses do not have a due date since it is self-paced, provided your account remains active and CBEHx has not discontinued the same program.